Original language | English |
---|---|
Pages (from-to) | 1-3 |
Number of pages | 3 |
Journal | Aging Clinical and Experimental Research |
Volume | 31 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jan 2019 |
Keywords
- CHOICE
- PHYSICIANS
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Aging Clinical and Experimental Research, Vol. 31, No. 1, 01.2019, p. 1-3.
Research output: Contribution to journal › Editorial › Academic › peer-review
TY - JOUR
T1 - Patients' preferences for osteoarthritis treatment
T2 - the value of stated-preference studies
AU - Hiligsmann, Mickael
AU - Pinto, Daniel
AU - Dennison, Elaine
AU - Al-Daghri, Nasser
AU - Beaudart, Charlotte
AU - Branco, Jaime
AU - Bruyere, Olivier
AU - Conaghan, Philip G.
AU - Cooper, Cyrus
AU - Herrero-Beaumont, Gabriel
AU - Jiwa, Famida
AU - Lems, Willem
AU - Rizzoli, Rene
AU - Thomas, Thierry
AU - Veronese, Nicola
AU - Reginster, Jean-Yves
N1 - Funding Information: No funding was received for this study. The authors are grateful to the Prince Mutaib Chair for Biomarkers of Osteoporosis, King Saud University, Riyadh, Saudi Arabia, for its support. Funding Information: Conflict of interest OB: research supports from Biophytis, IBSA, MEDA, Servier, SMB. PGC is supported in part by the UK NIHR Leeds Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. CC: lecture fees and honoraria from Amgen, Danone, Eli Lilly, GSK, Medtronic, Merck, Nestlé, Novartis, Pfizer, Roche, Servier, Shire, Takeda and UCB outside of the submitted work. TT: honorarium for lectures or advisory board from Abbvie, Amgen, Arrow, BMS, Chugai, Expanscience, Gilead, HAC-Pharma, LCA, Lilly, Medac, MSD, Pfizer, Thuasne, TEVA and UCB; research support from Amgen, Bone Therapeutics, Chugai, HAC-Pharma, MSD, Novartis, Pfizer, and UCB. JYR: consulting fees or paid advisory boards from IBSA-Genevrier, Mylan, Radius Health, Pierre Fabre, Teva; lecture fees when speaking at the invitation of sponsor: IBSA-Genevrier, Mylan, CNIEL, Dairy Research Council, Teva; Grant support from industry (all through institution) from IBSA-Genevrier, Mylan, CNIEL, Radius Health. OB research supports from Biophytis, IBSA, MEDA, Servier, SMB. NAD, CB, JB, CC, MH, GHB, FJ, DP, WL, and RR have no conflict of interest relevant to the content of this study.
PY - 2019/1
Y1 - 2019/1
KW - CHOICE
KW - PHYSICIANS
U2 - 10.1007/s40520-018-1098-3
DO - 10.1007/s40520-018-1098-3
M3 - Editorial
C2 - 30607878
SN - 1594-0667
VL - 31
SP - 1
EP - 3
JO - Aging Clinical and Experimental Research
JF - Aging Clinical and Experimental Research
IS - 1
ER -